(ICDs) play a crucial role in the treatment of patients at heightened risk of sudden cardiac
death (SCD) caused by ventricular arrhythmias. The use of ICDs for primary prevention is …

Such has been the case with the evolution of implantable cardioverter-defibrillator (ICD)
therapy. Evidence-based guidelines, national health care coverage determinations (CAG …

Background Primary prevention implantable cardioverter‐defibrillators (ICDs) reduce
mortality in selected patients with left ventricular systolic dysfunction by delivering therapies …

IDENTIFICATION OF PATIENTS AT RISK FOR SUDDEN CAR-diac death (SCD) is a major
challenge for the medical community. Although there have been advances in the area of risk …

Failure Trial (SCD-HeFT) prospectively tested the hypothesis that implantable cardioverter-
defibrillators (ICDs) could reduce mortality in patients at increased risk for sudden death …

Background—Although implantable cardioverter-defibrillators (ICDs) reduce mortality in
primary prevention patients with left ventricular systolic dysfunction, recent studies have …

Background—Implantable cardioverter-defibrillators (ICDs) are increasingly used for primary
prevention after randomized, controlled trials demonstrating that they reduce the risk of …

Background: Sudden cardiac death is common in persons with cardiovascular disease.
Purpose: To assess the efficacy of implantable cardioverter defibrillators (ICDs) in persons at …

Background Primary prevention implantable cardioverter defibrillator (ICD) reduce all-cause
mortality by reducing sudden cardiac death. There are conflicting data regarding whether …

Background—Underuse of implantable defibrillators has been previously noted in patients
at risk for sudden cardiac death, as well as for survivors of sudden cardiac death. We sought …